Skip to main content
Radcliffe Medical Education
Medical education learning resources for healthcare professionals
Radcliffe Medical Education banner
Radcliffe Medical Education banner
  • Home
  •  Severe Hypertriglyceridaemia: Defining the Disease and Its Management

Severe Hypertriglyceridaemia: Defining the Disease and Its Management

Topic:
  • CV Renal Metabolic
  • Prevention

Available Credit:

  • 1.00 EBAC

Course Published On:

Course Expiry Date:

Severe Hypertriglyceridaemia: Defining the Disease and Its Management
No ratings

Overview

Part of New Horizons in Dyslipidaemia (NHD) 2026, this expert-led symposium explores the rapidly evolving landscape of hypertriglyceridaemia (HTG) and the increasingly central role cardiologists play in its identification, risk stratification, and management.

 

As our understanding of triglyceride-rich lipoproteins deepens, so too does recognition of their contribution to residual cardiovascular risk and acute pancreatitis. This session brings together leading experts to examine HTG across the clinical spectrum—from common mixed dyslipidaemia to rare genetic disorders while highlighting emerging therapeutic targets and practical management strategies for cardiovascular specialists.

Support Statement

This symposium is supported by an unrestricted educational grant from Arrowhead Pharmaceuticals.

Disclosure

In compliance with EBAC guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. 

 

The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

Terms & Conditions

Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.

 

The session, Severe Hypertriglyceridaemia: Defining the Disease and Its Management’ is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credits.

 

Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

 

Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website.

Instruction to Participants

There is no fee for taking part in this online learning activity.

 

Activities are designed to be completed within 60 minutes and must be completed by the registered user. Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.

 

To complete the course and claim certification participants must:

 

  • Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity. Users must read and study the activity in its entirety before completing the post-test questions.
  • Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion.

Target Audience

Target Audience

  • General Cardiologists
  • Interventional Cardiologists
  • Lipid Specialists
  • Primary Care
  • Endocrinologists

Learning Objectives

  • Recall the mechanisms that make TGs a risk factor for atherosclerosis
  • Review how elevated FCS is a major risk factor for pancreatitis
  • Discuss the current clinical evidence of TG-lowering therapies in different disease states

Module

Title

Duration

Speakers

Part 1 Hypertriglyceridaemia: From Mixed Hyperlipidaemia to FCS 12m Erin D Michos (Baltimore, US)
Part 2 ApoC-III:An Emerging Target in HTG 23m Ioanna Gouni-Berthold (Cologne, DE)
Part 3 Management in Cardiology 14m Lale Tokgözoğlu (Ankara, TR)
Part 4 Panel Discussion and Audience Q&A 3m Ioanna Gouni-Berthold (Cologne, DE) Daniel Gaudet (Montreal, CA) Erin D Michos (Baltimore, US) Lale Tokgözoğlu (Ankara, TR)
Part 1.

Hypertriglyceridaemia: From Mixed Hyperlipidaemia to FCS

Duration: 12m

Speakers: Erin D Michos (Baltimore, US)

Part 2.

ApoC-III:An Emerging Target in HTG

Duration: 23m

Speakers: Ioanna Gouni-Berthold (Cologne, DE)

Part 3.

Management in Cardiology

Duration: 14m

Speakers: Lale Tokgözoğlu (Ankara, TR)

Chair

Daniel Gaudet

Daniel Gaudet

University of Montreal, Montreal, CA

Dr Daniel Gaudet founded the Université de Montréal Community Genomics Medicine Center, the Lipid Research Group and the Lipid Clinic at the Chicoutimi Hospital, where he was also director of research from 2003 to 2012.

View full profile

Speaker

Ioanna Gouni-Berthold

Ioanna Gouni-Berthold

University of Cologne, Cologne, DE

Prof Ioanna Gouni-Berthold is Professor of Internal Medicine and Head of the Lipid Research Clinic at the Policlinic for Endocrinology, Diabetes and Preventive Medicine at the University of Cologne in Germany.

View full profile

Lale Tokgözoğlu

Haceteppe University, Ankara, TR

Lale Tokgözoglu is Professor of Cardiology at Hacettepe University, Ankara, Turkey. She is currently the President of the European Atherosclerosis Society and Deputy Editor of the European Heart Journal.

View full profile
Erin Michos

Erin D Michos

Johns Hopkins University School of Medicine, Baltimore, MD, US

Dr Erin Michos is an Associate Professor of Medicine in the Division of Cardiology at the Johns Hopkins University School of Medicine, with joint appointment in the Department of Epidemiology at the Johns Hopkins Bloomberg School of Public Health.

View full profile
1.00 EBAC

Related Courses

Targeting Residual Inflammatory Risk: The Future of Cardiovascular Prevention
  • 1.00 EBAC

Learning objectives

  • Define residual inflammatory risk (RIR) and explain why cardiovascular events continue to occur in patients despite optimal lipid-lowering and antihypertensive therapies
  • Describe the pathophysiological role of inflammation in atherosclerosis, myocardial infarction, heart failure and chronic kidney disease
  • Identify patients at increased cardiovascular risk due to elevated inflammatory markers, particularly high-sensitivity C-reactive protein (hsCRP)
  • Interpret the clinical significance of hsCRP and other inflammatory biomarkers in primary and secondary prevention settings, in alignment with current evidence and guideline recommendations
  • Assess clinician practices, barriers and strategies for integrating inflammatory risk assessment and management
  • Apply key takeaways to inform future risk assessment and treatment decisions in patients with or at risk for cardiovascular disease
See more
The Rise of CVRM Medicine: Managing Common Co-morbidities as One
  • 3.00 EBAC

Learning objectives

  • Describe the link between T2DM, CKD and ASCVD
  • State the importance of early and effective intervention in managing CVRM disease progression
  • List the guideline directed therapeutic targets in CVRM disease
  • Select appropriate patients for holistic CVRM management
  • Recall trial data for novel therapeutic agents that carry benefit for CVRM outcomes
  • Develop a holistic management strategy for CVRM disease with an evidence-based impact on clinical outcomes
See more